Fig. 5From: Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysisNetwork analysis of progression-free survival and severe adverse events. The results of PFS are expressed as HRs (95% CrIs), and severe adverse events are expressed as RRs (95% CrIs). The data should be read from left to rightBack to article page